Memory-enhancing drugs sales will rise through 2036, driven by cholinesterase inhibitors at a 40% share in 2026 as the leading drug class segment. The market was valued at USD 7.9 billion in 2025 and is expected to reach USD 14.24 billion by 2036, creating an incremental opportunity of USD 5.91 billion.